Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

Inclusion criteria

• Malignant disease appropriate for initiating treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel, or erlotinib.
• Must be able to read, understand, and sign the IRB approved Informed Consent Form.
• At least 18 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Adequate bone marrow function; normal renal and hepatic function, normal cardiac function.

Exclusion criteria

• Any other active invasive malignancy except non-melanoma skin cancers or cervical carcinoma in situ.
• History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction.
• Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or hormonal therapy other than LHRH agonists.
• Received prior radiation therapy within the past 4 weeks.
• Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV.
• Patient requires treatment with immunosuppressive agents other than corticosteroids appropriate for the SOC chemotherapy regimen or those at stable doses for at least 2 weeks.